Imunon (NASDAQ:IMNN) Receives Buy Rating from D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued on Monday,Benzinga reports. They presently have a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.

Imunon Stock Performance

IMNN traded up $0.01 on Monday, hitting $0.96. 38,152 shares of the company were exchanged, compared to its average volume of 899,218. The business’s fifty day moving average is $0.89 and its 200 day moving average is $0.91. Imunon has a fifty-two week low of $0.64 and a fifty-two week high of $3.65. The firm has a market capitalization of $13.96 million, a P/E ratio of -0.51 and a beta of 1.96.

Institutional Investors Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Geode Capital Management LLC raised its stake in Imunon, Inc. (NASDAQ:IMNN) by 10.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the quarter. Geode Capital Management LLC owned about 0.96% of Imunon worth $133,000 at the end of the most recent quarter. 4.47% of the stock is owned by institutional investors and hedge funds.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.